Mylan has announced the UK launch of Brabio, the first available therapeutically equivalent version of the multiple sclerosis drug Copaxone.
The drug is indicated for the treatment of relapsing forms of multiple sclerosis and will be available at a lower acquisition cost to the NHS, which is currently seeking to expand its use of best-value medicines through its Medicines Value Programme.
This scheme aims to improve health outcomes by diverting spending to priority areas of need within the NHS without compromising on treatment quality, which creates significant opportunities for generic therapies such as Brabio.
Mylan has partnered with Synthon on the development and supply of this new drug, and has exclusive distribution and supply rights for the product across several European markets, including the UK.
Jacek Glinka, Mylan's European president, said: "We are dedicated to this important patient community and continued efforts to bring lower-cost, high-quality therapeutic equivalent versions of Copaxone to market in the UK and around the world."
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.